|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 107.00 SAR | +1.04% |
|
+9.18% | +12.63% |
| 03-09 | Tadawul All Share Index Tumbles as Triple-Digit Oil Weighs | MT |
| 03-09 | Nahdi Medical's FY25 Net Profit, Revenue Rise | MT |
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||
Return on Assets | 13.69 | 12.65 | 13.54 | 11.64 | 9.44 | |||
Return on Total Capital | 19.25 | 18.04 | 19.61 | 17.04 | 14.05 | |||
Return On Equity % | 43.96 | 44.13 | 46.16 | 37.93 | 32.51 | |||
Return on Common Equity | 43.96 | 44.13 | 46.16 | 37.93 | 32.51 | |||
Margin Analysis | ||||||||
Gross Profit Margin % | 36.95 | 40.23 | 40.05 | 39.43 | 36.43 | |||
SG&A Margin | 26.25 | 29.72 | 29.01 | 28.68 | 27.5 | |||
EBITDA Margin % | 12.86 | 13.23 | 13.84 | 13.55 | 11.96 | |||
EBITA Margin % | 11.2 | 11.23 | 11.62 | 11.03 | 9.23 | |||
EBIT Margin % | 11.2 | 11.23 | 11.6 | 11.03 | 9.23 | |||
Income From Continuing Operations Margin % | 9.82 | 10.07 | 10.3 | 10.24 | 8.69 | |||
Net Income Margin % | 9.82 | 10.07 | 10.3 | 10.24 | 8.69 | |||
Net Avail. For Common Margin % | 9.82 | 10.07 | 10.3 | 10.24 | 8.69 | |||
Normalized Net Income Margin | 6.62 | 6.49 | 6.91 | 6.77 | 5.5 | |||
Levered Free Cash Flow Margin | 8.56 | 8.83 | 11.86 | 7.29 | 8.44 | |||
Unlevered Free Cash Flow Margin | 8.98 | 9.44 | 12.43 | 7.65 | 8.93 | |||
Asset Turnover | ||||||||
Asset Turnover | 1.96 | 1.8 | 1.87 | 1.69 | 1.64 | |||
Fixed Assets Turnover | 4.41 | 3.81 | 4.01 | 3.97 | 3.76 | |||
Receivables Turnover (Average Receivables) | 73.91 | 67.56 | 63.71 | 57.51 | 61.27 | |||
Inventory Turnover (Average Inventory) | 4.71 | 4.26 | 4.49 | 4.07 | 3.85 | |||
Short Term Liquidity | ||||||||
Current Ratio | 1.76 | 1.4 | 1.7 | 1.69 | 1.55 | |||
Quick Ratio | 0.79 | 0.42 | 0.8 | 0.66 | 0.54 | |||
Operating Cash Flow to Current Liabilities | 1.13 | 1.07 | 1.11 | 0.84 | 0.74 | |||
Days Sales Outstanding (Average Receivables) | 4.95 | 5.4 | 5.73 | 6.35 | 5.97 | |||
Days Outstanding Inventory (Average Inventory) | 77.73 | 85.76 | 81.24 | 89.63 | 95.09 | |||
Average Days Payable Outstanding | 31.81 | 35.23 | 39.11 | 50.78 | 62.18 | |||
Cash Conversion Cycle (Average Days) | 50.87 | 55.94 | 47.86 | 45.21 | 38.88 | |||
Long Term Solvency | ||||||||
Total Debt/Equity | 57.97 | 84.75 | 52.07 | 47.7 | 59.15 | |||
Total Debt / Total Capital | 36.7 | 45.87 | 34.24 | 32.3 | 37.17 | |||
LT Debt/Equity | 39.88 | 61.84 | 35.31 | 35.35 | 44.32 | |||
Long-Term Debt / Total Capital | 25.24 | 33.47 | 23.22 | 23.93 | 27.85 | |||
Total Liabilities / Total Assets | 55.3 | 62.59 | 54.63 | 54.15 | 58.11 | |||
EBIT / Interest Expense | 16.83 | 11.48 | 12.6 | 19.04 | 11.82 | |||
EBITDA / Interest Expense | 25.4 | 18.42 | 19.85 | 30.83 | 20.99 | |||
(EBITDA - Capex) / Interest Expense | 20.26 | 14.84 | 16.7 | 23.82 | 16.39 | |||
Total Debt / EBITDA | 0.82 | 0.94 | 0.74 | 0.76 | 0.99 | |||
Net Debt / EBITDA | 0.13 | 0.66 | 0.06 | 0.17 | 0.37 | |||
Total Debt / (EBITDA - Capex) | 1.03 | 1.16 | 0.88 | 0.98 | 1.27 | |||
Net Debt / (EBITDA - Capex) | 0.17 | 0.82 | 0.07 | 0.22 | 0.47 | |||
Growth Over Prior Year | ||||||||
Total Revenues, 1 Yr. Growth % | 10.47 | -6.66 | 6.82 | 1.13 | 8.41 | |||
Gross Profit, 1 Yr. Growth % | 29.66 | 1.6 | 6.33 | -1.14 | 0.17 | |||
EBITDA, 1 Yr. Growth % | 15.39 | -3.89 | 11.42 | -0.97 | -4.29 | |||
EBITA, 1 Yr. Growth % | 16.52 | -6.28 | 10.11 | -4.02 | -9.27 | |||
EBIT, 1 Yr. Growth % | 16.6 | -6.23 | 10.36 | -3.91 | -9.27 | |||
Earnings From Cont. Operations, 1 Yr. Growth % | 22.7 | -4.31 | 9.27 | 0.54 | -8.05 | |||
Net Income, 1 Yr. Growth % | 22.7 | -4.31 | 9.27 | 0.54 | -8.05 | |||
Normalized Net Income, 1 Yr. Growth % | 16.37 | -8.55 | 13.67 | -0.9 | -11.88 | |||
Diluted EPS Before Extra, 1 Yr. Growth % | -93.86 | -4.31 | 9.27 | 0.54 | -8.05 | |||
Accounts Receivable, 1 Yr. Growth % | -31.88 | 42.42 | -7.19 | 32.75 | -21.61 | |||
Inventory, 1 Yr. Growth % | 4.15 | -2.82 | 5.94 | 19.16 | 21.39 | |||
Net Property, Plant and Equip., 1 Yr. Growth % | 0.76 | 9.63 | -6 | 10.9 | 17.88 | |||
Total Assets, 1 Yr. Growth % | 11.08 | -8.12 | 15.35 | 8.62 | 14.93 | |||
Tangible Book Value, 1 Yr. Growth % | 16.46 | -23.46 | 40.84 | 9.8 | 4.39 | |||
Common Equity, 1 Yr. Growth % | 16.5 | -22.86 | 39.9 | 9.78 | 5.01 | |||
Cash From Operations, 1 Yr. Growth % | 17.64 | -12.88 | 25.03 | -17.94 | 13.32 | |||
Capital Expenditures, 1 Yr. Growth % | 35.73 | -4.49 | -11.43 | 41.39 | -4.05 | |||
Levered Free Cash Flow, 1 Yr. Growth % | -23.57 | -5.89 | 43.49 | -38.92 | 23.51 | |||
Unlevered Free Cash Flow, 1 Yr. Growth % | -22.25 | -3.94 | 40.71 | -37.77 | 24.56 | |||
Dividend Per Share, 1 Yr. Growth % | - | - | - | 3.58 | 0 | |||
Compound Annual Growth Rate Over Two Years | ||||||||
Total Revenues, 2 Yr. CAGR % | 8.45 | 1.53 | -0.15 | 3.94 | 4.71 | |||
Gross Profit, 2 Yr. CAGR % | 25.41 | 14.77 | 3.94 | 2.89 | -0.49 | |||
EBITDA, 2 Yr. CAGR % | 17.47 | 5.22 | 3.64 | 5.04 | -2.64 | |||
EBITA, 2 Yr. CAGR % | 18.69 | 4.4 | 1.76 | 2.8 | -6.68 | |||
EBIT, 2 Yr. CAGR % | 19.32 | 4.47 | 1.73 | 2.98 | -6.63 | |||
Earnings From Cont. Operations, 2 Yr. CAGR % | 17.92 | 8.36 | 2.25 | 4.81 | -3.85 | |||
Net Income, 2 Yr. CAGR % | 17.92 | 8.36 | 2.25 | 4.81 | -3.85 | |||
Normalized Net Income, 2 Yr. CAGR % | 16.66 | 3.16 | 1.96 | 6.13 | -6.55 | |||
Diluted EPS Before Extra, 2 Yr. CAGR % | -73.63 | -78.75 | 2.25 | 4.81 | -3.85 | |||
Accounts Receivable, 2 Yr. CAGR % | -5.4 | 0.41 | 14.97 | 11 | 2.02 | |||
Inventory, 2 Yr. CAGR % | 2.14 | -0.77 | 1.47 | 12.36 | 20.27 | |||
Net Property, Plant and Equip., 2 Yr. CAGR % | 83.66 | 6.49 | 1.51 | 2.1 | 14.33 | |||
Total Assets, 2 Yr. CAGR % | 31.51 | 1.19 | 2.95 | 11.94 | 11.73 | |||
Tangible Book Value, 2 Yr. CAGR % | 11.5 | -5.58 | 3.83 | 24.36 | 7.06 | |||
Common Equity, 2 Yr. CAGR % | 11.27 | -5.2 | 3.88 | 23.93 | 7.37 | |||
Cash From Operations, 2 Yr. CAGR % | 27.21 | 1.24 | 2.55 | 1.29 | -5.44 | |||
Capital Expenditures, 2 Yr. CAGR % | 34.93 | 13.86 | -8.03 | 11.91 | 16.48 | |||
Levered Free Cash Flow, 2 Yr. CAGR % | 13.76 | -14.25 | 16.2 | -5.56 | -12.42 | |||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 16.49 | -12.67 | 16.26 | -6.43 | -11.27 | |||
Dividend Per Share, 2 Yr. CAGR % | - | - | - | - | 1.77 | |||
Compound Annual Growth Rate Over Three Years | ||||||||
Total Revenues, 3 Yr. CAGR % | 7 | 3.15 | 3.26 | 0.27 | 5.41 | |||
Gross Profit, 3 Yr. CAGR % | 15.75 | 16.91 | 11.89 | 2.46 | 1.97 | |||
EBITDA, 3 Yr. CAGR % | 7.9 | 9.81 | 7.36 | 2.08 | 1.84 | |||
EBITA, 3 Yr. CAGR % | 7.41 | 9.63 | 6.39 | -0.21 | -1.39 | |||
EBIT, 3 Yr. CAGR % | 8.26 | 10.04 | 6.4 | -0.19 | -1.28 | |||
Earnings From Cont. Operations, 3 Yr. CAGR % | 5.59 | 9.99 | 8.66 | 1.68 | 0.34 | |||
Net Income, 3 Yr. CAGR % | 5.59 | 9.99 | 8.66 | 1.68 | 0.34 | |||
Normalized Net Income, 3 Yr. CAGR % | 6.8 | 7.56 | 6.55 | 1 | -0.25 | |||
Diluted EPS Before Extra, 3 Yr. CAGR % | - | -62.87 | -63.32 | 1.68 | 0.34 | |||
Accounts Receivable, 3 Yr. CAGR % | -4.22 | 9.82 | -2.19 | 20.62 | -1.15 | |||
Inventory, 3 Yr. CAGR % | -1.26 | -0.46 | 1.42 | 7.05 | 15.29 | |||
Net Property, Plant and Equip., 3 Yr. CAGR % | 37.12 | 56 | 2.15 | 4.55 | 7.11 | |||
Total Assets, 3 Yr. CAGR % | 21.83 | 16.82 | 5.71 | 4.8 | 12.93 | |||
Tangible Book Value, 3 Yr. CAGR % | 8.77 | -1.64 | 7.88 | 5.78 | 17.31 | |||
Common Equity, 3 Yr. CAGR % | 8.5 | -1.52 | 7.93 | 5.81 | 17.27 | |||
Cash From Operations, 3 Yr. CAGR % | 20.31 | 12.13 | 7.35 | -4.79 | 3.79 | |||
Capital Expenditures, 3 Yr. CAGR % | 20.82 | 20.25 | 4.71 | 6.15 | 6.31 | |||
Levered Free Cash Flow, 3 Yr. CAGR % | - | 7.58 | 1.8 | -5.67 | 3.85 | |||
Unlevered Free Cash Flow, 3 Yr. CAGR % | - | 10 | 2.38 | -5.6 | 3.48 | |||
Compound Annual Growth Rate Over Five Years | ||||||||
Total Revenues, 5 Yr. CAGR % | - | - | 4.07 | 3.46 | 3.84 | |||
Gross Profit, 5 Yr. CAGR % | - | - | 10.87 | 11.09 | 6.91 | |||
EBITDA, 5 Yr. CAGR % | - | - | 6.14 | 7.94 | 3.24 | |||
EBITA, 5 Yr. CAGR % | - | - | 5.08 | 6.92 | 0.95 | |||
EBIT, 5 Yr. CAGR % | - | - | 5.56 | 7.16 | 0.98 | |||
Earnings From Cont. Operations, 5 Yr. CAGR % | - | - | 4.24 | 7.89 | 3.47 | |||
Net Income, 5 Yr. CAGR % | - | - | 4.24 | 7.89 | 3.47 | |||
Normalized Net Income, 5 Yr. CAGR % | - | - | 4.83 | 6.99 | 1.1 | |||
Diluted EPS Before Extra, 5 Yr. CAGR % | - | - | - | -43.77 | -46.07 | |||
Accounts Receivable, 5 Yr. CAGR % | - | - | 3.83 | 10.29 | -0.53 | |||
Inventory, 5 Yr. CAGR % | - | - | -0.72 | 4.48 | 8.57 | |||
Net Property, Plant and Equip., 5 Yr. CAGR % | - | - | 22.22 | 31.67 | 6.86 | |||
Total Assets, 5 Yr. CAGR % | - | - | 13.97 | 14.84 | 8.08 | |||
Tangible Book Value, 5 Yr. CAGR % | - | - | 6.77 | 8.03 | 7.55 | |||
Common Equity, 5 Yr. CAGR % | - | - | 6.63 | 7.96 | 7.7 | |||
Cash From Operations, 5 Yr. CAGR % | - | - | 12.86 | 6.91 | 2.04 | |||
Capital Expenditures, 5 Yr. CAGR % | - | - | 8.33 | 16.84 | 9.27 | |||
Levered Free Cash Flow, 5 Yr. CAGR % | - | - | - | 2.12 | -3.81 | |||
Unlevered Free Cash Flow, 5 Yr. CAGR % | - | - | - | 3.11 | -3.31 |
- Stock Market
- Equities
- 4164 Stock
- Financials Nahdi Medical Company
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















